AIM ImmunoTech (AIM) Long-Term Deferred Tax (2015 - 2016)
AIM ImmunoTech's (AIM) quarterly Long-Term Deferred Tax came in at $59.1 million in Q4 2016, up 3.42% YoY from $57.1 million in Q1 2016, and up 3.42% on a QoQ basis from $57.1 million in Q4 2015.
AIM ImmunoTech (AIM) Long-Term Deferred Tax (2015 - 2016) Analysis & Trends
AIM ImmunoTech (AIM) has 2 years of Long-Term Deferred Tax data on file, last reported at $59.1 million in Q4 2016.
- Quarterly Long-Term Deferred Tax rose 3.42% year-over-year to $59.1 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $59.1 million (up 3.42% YoY) and the FY2016 annual result came in at $59.1 million, up 3.42% from the prior year.
- Long-Term Deferred Tax climbed to $59.1 million in Q4 2016, from $57.1 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $59.1 million in Q4 2016 to a low of $57.1 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | AIM ImmunoTech | 4.45 Mn | -5.52 Mn | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 59.10 Mn |
| Dec 31, 2015 | 57.14 Mn |